Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β (2021)
- Authors:
- Autor USP: CONDINO NETO, ANTONIO - ICB
- Unidade: ICB
- DOI: 10.1007/s10875-021-01068-6
- Subjects: IMUNOLOGIA; IMUNIDADE; IMUNODEFICIÊNCIA DE VARIÁVEL COMUM; IMUNOGENÉTICA; COVID-19; INTERFERON TIPO I; INFECÇÕES POR CORONAVIRUS; ESTUDOS DE COORTES
- Agências de fomento:
- Financiamento St. Giles Foundation
- Financiamento NIH
- Financiamento National Center for Advancing Translational Sciences
- Financiamento Clinical and Translational Science Award
- Financiamento NHGRI/NIH
- Financiamento Fisher Center for Alzheimer’s Research Foundation
- Financiamento Meyer Foundation
- Financiamento ANR
- Financiamento Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence
- Financiamento French Foundation for Medical Research
- Financiamento ANR GENCOVID
- Financiamento Square Foundation
- Financiamento SCOR Corporate Foundation for Science
- Financiamento Institut National de la Santé et de la Recherche Médicale
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Clinical Immunology
- ISSN: 1573-2592
- Volume/Número/Paginação/Ano: p. 1-18, 2021
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: other-oa
-
ABNT
VINH, Donald C. et al. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. Journal of Clinical Immunology. New York: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1007/s10875-021-01068-6. Acesso em: 19 abr. 2024. , 2021 -
APA
Vinh, D. C., Abel, L., Bastard, P., Cheng, M. P., Condino Neto, A., Gregersen, P. K., et al. (2021). Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. Journal of Clinical Immunology. New York: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1007/s10875-021-01068-6 -
NLM
Vinh DC, Abel L, Bastard P, Cheng MP, Condino Neto A, Gregersen PK, Haerynck F, Cicalese M-P, Hagin D, Palacín PS, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova J-L, Meyts I. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β [Internet]. Journal of Clinical Immunology. 2021 ; 1-18.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1007/s10875-021-01068-6 -
Vancouver
Vinh DC, Abel L, Bastard P, Cheng MP, Condino Neto A, Gregersen PK, Haerynck F, Cicalese M-P, Hagin D, Palacín PS, Planas AM, Pujol A, Notarangelo LD, Zhang Q, Su HC, Casanova J-L, Meyts I. Harnessing Type I IFN immunity against SARS-CoV-2 with early administration of IFN-β [Internet]. Journal of Clinical Immunology. 2021 ; 1-18.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1007/s10875-021-01068-6 - Anhidrotic ectodermal dysplasia and T cell immunodeficiency
- BAY 41-2272 aumenta a atividade microbicida in vitro de leucócitos mononucleares humanos
- The role of nuclear factor kappa B (NF-kB) on the NCF1 gene expression
- Essential role of nuclear factor-kappa B for NADPH oxidase activity in normal and anhidrotic ectodermal dysplasia leukocytes
- A single nucleotide polymorphism in the promoter region of the NCF-2 gene
- Essential role of nuclear factor-kappa B for NADPH oxidase activity, CYBB and NCF-1 gene expression in normal and anhidrotic ectodermal dysplasia leukocytes
- An unusual case of a female patient presenting with recurrent infections due to mycobacteria, viruses, and pyogenic bacteria and defective TLRs response
- Critical issues and needs in management of primary immunodeficiency diseases in Latin America
- Brain abscess as first clinical manifestation of hypogammaglobulinemia
- Essential role of Nuclear Factor kappa B (NF-jB) on NCFL gene expression in normal, anhidrotic ectodermal dysplasia, and chronic granulomatous disease leukocytes
Informações sobre o DOI: 10.1007/s10875-021-01068-6 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
